Inhibition of human cytochrome P450 enzymes by metallic nanoparticles: A preliminary to nanogenomics

International Journal of Pharmacology

Volumn 4, Issue 6, 2008, Pages 492-495

  Sereemaspun, A ^a   Hongpiticharoen, P ^a   Rojanathanes, R ^a   Maneewattanapinyo, P ^a   Ekgasit, S ^a   Warisnoicharoen, Warangkana ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Cytochrome P450; Gold nanoparticles; Metabolism; Silver nanoparticles

Indexed keywords

COMPLEMENTARY DNA; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; GOLD; METAL NANOPARTICLE; NANOMATERIAL; NANOPARTICLE; SILVER;

AEROBIC METABOLISM; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; GENOMICS; HUMAN; IN VITRO STUDY; LIPOPHILICITY; MICROSOME MEMBRANE; NANOGENOMICS; PARTICLE SIZE; PROTEIN EXPRESSION; PROTEIN INTERACTION; WILD TYPE;

EID: 63749130064     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2008.492.495     Document Type: Article

References (12)

1. Bhattacharya, R., C.R. Patra, R. Verma, S. Kumar and P.R. Greipp et al., 2007. Gold nanoparticles inhibit the proliferation of multiple myeloma cells. Adv. Mater., 19: 711-716.
2. Biju, V., T. Itoh, A. Anas, A. Sujith and M. Ishikawa, 2008. Semiconductor quantum dots and metal nanoparticles: Syntheses, optical properties, and biological applications. Anal. Bioanal. Chem., 391: 2469-2495.
3. Coleman, M.D., 2005. Human Drug Metabolism. 1st Edn., John Wiley and Sons, Chichester, ISBN-13 978-0-470-86353-6.
4. Elechiguerra, J.L., J.L. Burt, J.R. Morones, A. Camacho-Bragado and X. Gao et al., 2005. Interaction of silver nanoparticles with HIV-1. J. Nanobiotechnol., 3: 1-10.
5. Enüstün, B.V. and J. Turkevich, 1963. Coagulation of colloidal gold. J. Am. Chem. Soc., 85: 3317-3328.
6. Farokhzad, O.C. and R. Langer, 2006. Nanomedicine: Developing smarter therapeutic and diagnostic modalities. Adv. Drug Deliv. Rev., 58: 1456-1459.
7. Fischer, N.O., C.M. McIntosh, J.M. Simard and V.M. Rotello, 2002. Inhibition of chymotrypsin through surface binding using nanoparticle-based receptors. Proc. Natl. Acad. Sci. USA., 99: 5018-5023.
8. Lewis, D.F.V., M.N. Jacobs and M. Dickins, 2004. Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Discov. Today, 9: 530-537.
9. Lopez, C.F., S.O. Nielsen, P.B. Moore and M.L. Klein, 2004. Understanding nature's design for a nanosyringe. Proc. Natl. Acad. Sci. USA., 101: 4431-4434.
10. Mountfield, R.J., S. Senepin, M. Schleimer, I. Walter and B. Bittner, 2000. Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450. Int. J. Pharm., 211: 89-92.
11. Mukherjee, P., R. Bhattacharya, P. Wang, L. Wang and S. Basu et al., 2005. Antiangiogenic properties of gold nanoparticles. Clin. Cancer Res., 11: 3530-3534.
12. Van Hyning, D.L. and C.F. Zukoski, 1998. Formation mechanism and aggregation behavior of borohydride reduced silver particles. Langmuir, 14: 7034-7046.